Evidence map›Paper›PMID 38647327›Full record

ArticleJournal of virology2024

A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.

Daniel Thoresen, Kenta Matsuda, Akane Urakami, Mya Myat Ngwe Tun, Takushi Nomura, Meng Ling Moi, Yuri Watanabe, Momoko Ishikawa, Trang Thi Thu Hau, Hiroyuki Yamamoto and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Daniel Thoresen *VLP Therapeutics, Inc., Gaithersburg, Maryland, USA.ORCID 0000-0002-8292-3137
Kenta Matsuda *VLP Therapeutics, Inc., Gaithersburg, Maryland, USA.ORCID 0000-0001-7746-3028
Akane UrakamiVLP Therapeutics, Inc., Gaithersburg, Maryland, USA.
Mya Myat Ngwe TunDepartment of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Takushi NomuraAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Meng Ling MoiDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Yuri WatanabeVLP Therapeutics, Inc., Gaithersburg, Maryland, USA.
Momoko IshikawaVLP Therapeutics, Inc., Gaithersburg, Maryland, USA.
Trang Thi Thu HauAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroyuki YamamotoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Yuriko SuzakiManagement Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo, Japan.
Yasushi AmiManagement Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo, Japan.
Jonathan F SmithVLP Therapeutics, Inc., Gaithersburg, Maryland, USA.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kouichi MoritaDepartment of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Wataru AkahataVLP Therapeutics, Inc., Gaithersburg, Maryland, USA.ORCID 0000-0001-9207-6923
VLP Therapeutics (United States) · USNational Institute of Infectious Diseases · JPNagasaki University · JP

Funding

Global Health Innovative Technology Fund (GHIT) G2016-109
6 · The paper itself

Abstract

Dengue virus (DENV) represents a significant global health burden, with 50% of the world's population at risk of infection, and there is an urgent need for next-generation vaccines. Virus-like particle (VLP)-based vaccines, which mimic the antigenic structure of the virus but lack the viral genome, are an attractive approach. Here, we describe a dengue VLP (DENVLP) vaccine which generates a neutralizing antibody response against all four DENV serotypes in 100% of immunized non-human primates for up to 1 year. Additionally, DENVLP vaccination produced no ADE response against any of four DENV serotypes

Indexed as

Antibodies, NeutralizingAntibodies, ViralDengueDengue VaccinesDengue VirusVaccines, Virus-Like ParticleAnimalsDisease Models, AnimalFemaleImmunoglobulin GMacaca fascicularisMacaca mulattaMiceSerogroupVaccinationVirus ReplicationAntibodies, NeutralizingAntibodies, ViralDengue VaccinesImmunoglobulin GVaccines, Virus-Like ParticlechallengedengueNHPvaccineVLP

Identifiers

PMID38647327
PMCPMC11092354
OpenAlexW4395011844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.